Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesImmunoGen Announces Amgen has Licensed Rights to Use the Companys TAP Technology for a Solid Tumor Target
ImmunoGen, Inc., 09/17/09
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Sponsor
Article Search
Sponsor